Naperville, IL -- (SBWIRE) -- 09/30/2013 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Alzheimers Disease - France Drug Forecast and Market Analysis to 2022 market report to its offering
PharmaPoint: Alzheimers Disease - France Drug Forecast and Market Analysis to 2022
Summary
The publisher has released its new Country report, PharmaPoint: Alzheimers Disease - France Drug Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimers Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease._x000D_
France has established specialized AD facilities that have made diagnosis much easier in the rural areas of the country. Moreover, accessibility to affordable medications in France is among the highest of the EU countries. However, there is an widespread notion among family physicians in the EU that referral of an AD patient to specialists is sometimes not in the best interest of their patient, which prevents patients from proceeding along the usual pathway to the most effective management.
Scope
- Overview of Alzheimers Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for the top drugs in France from 2012-2022._x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting France Alzheimers Disease market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimers Disease_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in France
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/143129/pharmapoint-alzheimers-disease-france-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###